Physician profile
Emily Renda
NPI 1003360231
$11,925.75
in general payments reported to CMS, 2019-2025
38 companies · $4,046 in 2025
The $4,046 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $2,174 · 2023: $2,305 · 2024: $3,258 · 2025: $4,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,582 · Education: $26.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,582.39 |
| Education | $26.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,327.99 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,777.88 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $701.86 | 2022-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $652.12 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $640.14 | 2022-2025 | Xifaxan, Plenvu |
| Pfizer INC. | $635.50 | 2022-2025 | |
| Madrigal Pharmaceuticals | $438.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $433.65 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $330.55 | 2023-2025 | Voquezna |
| Genzyme Corporation | $310.66 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $252.27 | 2022-2025 | Rebyota |
| Ardelyx, INC. | $237.61 | 2023-2025 | Ibsrela |
| Celgene Corporation | $209.93 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $192.35 | 2021-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $192.02 | 2022-2025 | Dupixent |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $191.73 | 2024 | Interstim, Gi Genius |
| Nestle Healthcare Nutrition INC. | $186.43 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $145.01 | 2024-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $130.30 | 2022-2025 | Injectafer |
| Janssen Scientific Affairs, LLC | $117.78 | 2024 | Tremfya |
| Intercept Pharmaceuticals, INC. | $112.47 | 2022-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $111.15 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $99.58 | 2022 | |
| Redhill Biopharma INC. | $80.02 | 2022 | |
| Novo Nordisk INC | $69.24 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.14 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $35.92 | 2023-2025 | Sutab, Suflave |
| Amgen INC. | $34.49 | 2023 | Amjevita, Avsola |
| Sandoz INC. | $33.13 | 2023 | Hyrimoz |
| Orphalan INC | $32.15 | 2025 | Cuvrior |
| Organon LLC | $30.91 | 2023-2024 | Renflexis |
| Exact Sciences Corporation | $28.20 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $24.15 | 2024 | Dificid |
| Teva Pharmaceuticals USA, INC. | $18.19 | 2024 | Simlandi |
| Capsovision, INC. | $17.32 | 2025 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $16.71 | 2024 | |
| Pharmacosmos Therapeutics INC. | $15.91 | 2025 | Monoferric |
| Evoke Pharma, INC. | $14.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Renda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.